Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.63 |
| ▸ | AHCY | P23526 | 2/20 | 0.63 |
| ▸ | ADCY5 | O95622 | 9/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.59 |
| ▸ | PI4KA | P42356 | 3/20 | 0.58 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.58 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.58 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12858753 | 1.00 | ADORA2A (0.64) | ADORA2AADORA2BAHCYADCY5ADORA3 | |
| SCHEMBL9309056 | 0.91 | ADORA2A (0.69) | ADORA2AADORA2BAHCYADCY5ADORA3 | |
| SCHEMBL9308668 | 0.91 | ADORA2A (0.69) | ADORA2AADORA2BAHCYADCY5ADORA3 | |
| SCHEMBL9687054 | 0.90 | AHCY (0.66) | ADORA2AADORA2BAHCYADORA3ADORA1 | |
| SCHEMBL12157236 | 0.90 | AHCY (0.66) | ADORA2AADORA2BAHCYADORA3ADORA1 | |
| SCHEMBL12173989 | 0.90 | AHCY (0.66) | ADORA2AADORA2BAHCYADORA3ADORA1 | |
| SCHEMBL9308490 | 0.86 | AHCY (0.70) | ADORA2AADORA2BAHCYADCY5ADORA3 | |
| SCHEMBL10474172 | 0.84 | ADCY5 (0.74) | ADORA2AADORA2BAHCYADCY5ADORA3 | |
| SCHEMBL9311283 | 0.83 | AHCY (0.83) | ADORA2AADORA2BAHCYADORA3ADORA1 | |
| SCHEMBL9309719 | 0.83 | AHCY (0.83) | ADORA2AADORA2BAHCYADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176813-A1 | CARBOCYCLIC NUCLEOSIDES AND PROCESS FOR OBTAINING SUCH | STICHTING REGA VZW (BE) | 2008-07-24 | — | — | US | disclosed |
| EP-1210347-B1 | CARBOCYCLIC NUCLEOSIDES AND PROCESS FOR OBTAINING SUCH | STICHTING REGA V Z W (BE) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176813-A1 | CARBOCYCLIC NUCLEOSIDES AND PROCESS FOR OBTAINING SUCH | ATIC, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA2B 4/4885AHCY 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.